SBIR/STTR Research Award
Highly-Multiplexed Capillary Electrophoresis
Award amount
$99,420Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CombiSep, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The explosive growth in biological,
pharmaceutical, and human health screening technologies has challenged the
analytical sciences to create methodologies for high-sample throughput. Of the
many possible methodologies, capillary electrophoresis (CE) has an unrecognized
potential to serve as a platform for a highly multiplexed analysis system that
allows for extremely high sample throughput. However, CE traditionally suffers
from unacceptably high sample-to-sample and capillary-to-capillary variations
in elution profiles and injection volumes. This variability is one of the main
impediments to the use of CE in routine analysis. Furthermore, today's
multiplexed CE systems are based only on fluorescence read-out concepts, which
are ineffective in detecting -90 percent of the likely target compounds. This
project describes the design fabrication, and implementation of a 96-capillary
array CE system that 1) employs an absorbance-based read-out methodology and 2)
utilizes the near-continuous measurement, collection, and application of the
current flow at each individual capillary. The former significantly expands the
scope of the system. The latter uses the collected current for
self-normalization of the electropherogram through application of the migration
index, which can yield precisions that compare favorably with that of high
performance liquid chromatography. Success in Phase I will lead to a Phase II
program focused on optimizing the system and methods to test biological fluids
to perform disease diagnosis and/or prognosis as well as combinatorial drug
synthesis and activity screening. Phase II would accumulate in actual field
tests being performed and compared to traditional, accepted methods.
PROPOSED COMMERCIAL APPLICATION:
The ultimate goal of the project for commercial applications is the creation of a packaged
system that has proven capabilities for solving problems in the health-related applications
(e.g., cancer gene detection, multation analysis, forensic genotyping and drug efficacy)
and other areas demanding reliable, high throughput analysis.
Technology keywords
Not reported